Literature DB >> 7914035

Hyperthermia increases intercellular adhesion molecule-1 expression and lymphocyte adhesion to endothelial cells.

A T Lefor1, C E Foster, W Sartor, B Engbrecht, D F Fabian, D Silverman.   

Abstract

BACKGROUND: We observed that the synergistic combination of immunotherapy and whole-body hyperthermia is active against large well-vascularized tumors but not microscopic tumors, and we therefore hypothesized that hyperthermia may act on lymphocyte-endothelial cell interactions. We undertook these studies to evaluate the effect of hyperthermia on lymphocyte-endothelial cell adhesion.
METHODS: Cultured human umbilical vein endothelial cells (HUVEC) and normal peripheral blood lymphocytes were used. HUVEC were cultured to confluence. Treatment groups included control, hyperthermia alone (41 degrees C for 2 hours), interferon-gamma (IFN-gamma) alone, or hyperthermia + interferon-gamma. 51Cr-labeled peripheral blood lymphocytes were allowed to adhere to treated HUVEC, and nonadhering cells were washed away. Adherent cells were lysed and counted in a gamma-counter, calculating an adhesion index compared to controls. The experiment was then conducted with the addition of anti-intercellular adhesion molecule (ICAM) antibody. Cell surface ICAM expression was determined with double monoclonal antibody staining and fluorescence-activated cell sorter analysis, and soluble ICAM secretion was determined with enzyme-linked immunosorbent assay in each group.
RESULTS: In a representative experiment, interferon-gamma increased adhesion by a factor of 1.81 (p < 0.05) compared with control and hyperthermia by 1.38 (p < 0.05) and combined treatment by a factor of 2.43 (p < 0.05). Anti-ICAM antibody abrogated the increased adhesion caused by hyperthermia but did not abrogate the effect of interferon-gamma. Although only 26% of control cells expressed ICAM-1 on the cell surface, interferon-gamma increased expression to 53% (p < 0.05), hyperthermia increased expression to 38% (p < 0.05), and combined treatment increased expression to 61% (p < 0.05). Soluble ICAM-1 was not increased 12 hours after treatment, but by 24 hours significant (p < 0.05) differences (control 0.262 ng/ml, IFN alone 1.50, hyperthermia alone 1.57, and combined 2.71) were noted.
CONCLUSIONS: These results suggest that hyperthermia has a significant effect on lymphocyte adhesion to endothelial cells, at least in part mediated by ICAM-1. Cell surface ICAM-1 is increased at 12 hours, and soluble ICAM-1 is increased at 24 hours. These data suggest that hyperthermia may function by increasing lymphocyte adhesion, providing another locus of action to improve clinical results with immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914035

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

Review 1.  Fever and the thermal regulation of immunity: the immune system feels the heat.

Authors:  Sharon S Evans; Elizabeth A Repasky; Daniel T Fisher
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

2.  Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.

Authors:  R J Griffin; S H Lee; K L Rood; M J Stewart; J C Lyons; Y S Lew; H Park; C W Song
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

Review 3.  Non-pharmacological interventions for vascular health and the role of the endothelium.

Authors:  Helen M McGettrick; Samuel J E Lucas; Samuel R C Weaver; Catarina Rendeiro; Rebekah A I Lucas; N Timothy Cable; Tom E Nightingale
Journal:  Eur J Appl Physiol       Date:  2022-09-23       Impact factor: 3.346

4.  Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines.

Authors:  T D Quinn; H C Polk; M J Edwards
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

5.  Comparison between interstitial laser thermotherapy and excision of an adenocarcinoma transplanted into rat liver.

Authors:  P H Möller; K Ivarsson; U Stenram; M Radnell; K G Tranberg
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.